These structural motifs can be found in the MC4R antagonist PF-07258669 in phase 1 clinical trials from Pifzer and in the development of the FGFR4 selective inhibitor Roblitinib from Novartis.

Water Environment and Health Henan Engineering Technology Research Center, Zhengzhou 451100, Henan, China School of Pharmacy and Chemical Engineering, Zhengzhou University of Industrial Technology, ...